Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Recent progress in genetic variation and risk of antituberculosis drug-induced liver injury.

Journal of the Chinese Medical Association : JCMA - 1 Apr 2014

Huang Yi-Shin

Abstract excerpt

Antituberculosis drug-induced liver injury (ATDILI) is the most prevalent hepatotoxicity in many countries. All of the three first-line antituberculosis drugs, isoniazid, rifampicin, and pyrazinamide, may induce hepatic damage, especially isoniazid. The major drug-metabolizing enzyme of isoniazid is N-acetyltransferase (NAT). Other possible enzymes are CYP2E1, glutathione S-transferase (GST) and manganese...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antitubercular Agents
Share to Arylamine N-Acetyltransferase
Share to Chemical and Drug Induced Liver Injury

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to NAT2 gene

Share to SOD2 gene

Share to Genetic Variation

Share to Glutathione Transferase

Share to Superoxide Dismutase

Source

Identifiers

PMID: 24593909
DOI: 10.1016/j.jcma.2014.01.010

Genes

NAT2
GSTM1
SOD2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Recent progress in genetic variation and risk of antituberculosis drug-induced liver injury.PMID 24593909Read ↗

Genetic polymorphisms of drug-metabolizing enzymes and the susceptibility to antituberculosis drug-induced liver injury.Semantic proximity Read ↗

Pharmacogenetic study of drug-metabolising enzyme polymorphisms on the risk of anti-tuberculosis drug-induced liver injury: a meta-analysis.Semantic proximity Read ↗

Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis.Semantic proximity Read ↗

Antituberculosis drug-induced hepatitis: risk factors, prevention and management.Semantic proximity Read ↗

N-acetyltransferase and cytochrome P450 2E1 gene polymorphisms and susceptibility to antituberculosis drug hepatotoxicity in an Indian population.Semantic proximity Read ↗

Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis.Semantic proximity Read ↗

Slow N-acetyltransferase 2 genotype contributes to anti-tuberculosis drug-induced hepatotoxicity: a meta-analysis.Semantic proximity Read ↗

Genetic polymorphisms in metabolic enzymes and susceptibility to anti-tuberculosis drug-induced hepatic injury.Semantic proximity Read ↗

Genetic association studies in drug-induced liver injury.Semantic proximity Read ↗

N-acetyltransferase 2, cytochrome P4502E1 and glutathione S-transferase genotypes in antitubercular treatment-induced hepatotoxicity in North Indians.Semantic proximity Read ↗

Polymorphisms of NAT2, CYP2E1, GST, and HLA related to drug-induced liver injury in indonesian tuberculosis patientsSemantic proximity Read ↗

Role of polymorphic N-acetyl transferase2 and cytochrome P4502E1 gene in antituberculosis treatment-induced hepatitis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.